Global Chronic Rhinosinusitis With Nasal Polyps Market Analysis 2024 – Estimated Market Size And Key Drivers

The Chronic Rhinosinusitis With Nasal Polyps Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Chronic Rhinosinusitis With Nasal Polyps Market:
https://www.thebusinessresearchcompany.com/report/chronic-rhinosinusitis-with-nasal-polyps-global-market-report

According to The Business Research Company’s Chronic Rhinosinusitis With Nasal Polyps Global Market Report 2024, The chronic rhinosinusitis with nasal polyps market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%.  The growth in the forecast period can be attributed to growing biologic therapies, increasing personalized medicine, advancing technological advancements, increasing regulatory approvals, growing patient-centric care, and monitoring epidemiological trends. Major trends in the forecast period include innovative drug delivery systems, understanding pathophysiology, clinical trials, longitudinal studies, increased awareness, integrated care models, prevalence, and incidence.

The increasing prevalence of respiratory diseases is expected to propel the growth of chronic rhinosinusitis with the nasal polyps market going forward. Respiratory diseases encompass a broad range of conditions that affect the respiratory system, including the lungs and airways. A complex interplay of factors, including air pollution, smoking, climate change, infections, occupational exposures, and allergies, drives the rising cases of respiratory diseases. With more people experiencing conditions such as asthma and chronic obstructive pulmonary disease (COPD), the incidence of associated conditions such as CRSwNP also rises, resulting in greater demand for diagnostic tools, treatments, and surgical interventions. For instance, in May 2024, according to the data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, asthma episodes in the adult group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the increasing prevalence of respiratory tract infections will drive the growth of the chronic rhinosinusitis with nasal polyps market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=17113&type=smp

The chronic rhinosinusitis with nasal polyps market covered in this report is segmented –
1) By Treatment: Medications, Surgical Methods
2) By Route Of Administration: Nasal, Oral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Major companies operating in the chronic rhinosinusitis with nasal polyps’ market are focusing on alternative therapies, such as anti-IL-5 biologics, to improve patient outcomes and gain a competitive advantage. Anti-IL-5 biologics offer targeted therapy that reduces eosinophilic inflammation in diseases like severe asthma and eosinophilic disorders, improving symptom control and quality of life for patients. For instance, in July 2021, GlaxoSmithKline (GSK), a U.K.-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5 (IL-5), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the indication of mepolizumab to include add-on maintenance therapy for adult patients aged 18 and older who have not adequately responded to nasal corticosteroids. Mepolizumab is approved for severe eosinophilic asthma in patients aged six and older, and it’s the first biologic for adults with eosinophilic granulomatosis with polyangiitis (EGPA) and patients aged 12 and older with hypereosinophilic syndrome (HES).

The chronic rhinosinusitis with nasal polyps market report table of contents includes:
1. Executive Summary

2. Chronic Rhinosinusitis With Nasal Polyps Market Characteristics
3. Chronic Rhinosinusitis With Nasal Polyps Market Trends And Strategies
4. Chronic Rhinosinusitis With Nasal Polyps Market – Macro Economic Scenario
5. Global Chronic Rhinosinusitis With Nasal Polyps Market Size and Growth

.

32. Global Chronic Rhinosinusitis With Nasal Polyps Market Competitive Benchmarking
33. Global Chronic Rhinosinusitis With Nasal Polyps Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chronic Rhinosinusitis With Nasal Polyps Market
35. Chronic Rhinosinusitis With Nasal Polyps Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model